Literature DB >> 16434160

Evidence for lower variability of coronary artery calcium mineral mass measurements by multi-detector computed tomography in a community-based cohort--consequences for progression studies.

Udo Hoffmann1, Uwe Siebert, Arabella Bull-Stewart, Stephan Achenbach, Maros Ferencik, Fabian Moselewski, Thomas J Brady, Joseph M Massaro, Christopher J O'Donnell.   

Abstract

PURPOSE: To compare the measurement variability for coronary artery calcium (CAC) measurements using mineral mass compared with a modified Agatston score (AS) or volume score (VS) with multi-detector CT (MDCT) scanning, and to estimate the potential impact of these methods on the design of CAC progression studies.
MATERIALS AND METHODS: We studied 162 consecutive subjects (83 women, 79 men, mean age 51 +/- 11 years) from a general Caucasian community-based cohort (Framingham Heart Study) with duplicate runs of prospective electrocardiographically-triggered MDCT scanning. Each scan was independently evaluated for the presence of CAC by four experienced observers who determined a "modified" AS, VS and mineral mass.
RESULTS: Of the 162 subjects, CAC was detected in both scans in 69 (42%) and no CAC was detected in either scan in 72 (45%). Calcium scores were low in the 21/162 subjects (12%) for whom CAC was present in one but not the other scan (modified AS < 20 in 20/21 subjects, mean AS 4.6 +/- 1.9). For all three quantification algorithms, the inter- and intraobserver correlation were excellent (r > 0.96). However, the mean interscan variability was significantly different between mineral mass, modified AS, and VS (coefficient of variation 26 +/- 19%, 41 +/- 28% and 34 +/- 25%, respectively; p < 0.04), with significantly smaller mean differences in pair-wise comparisons for mineral mass compared with modified AS (p < 0.002) or with VS (p < 0.03). The amount of CAC but not heart rate was an independent predictor of interscan variability (r = -0.638, -0.614 and -0.577 for AS, VS, and mineral mass, respectively; all p < 0.0001). The decreased interscan variability of mineral mass would allow a sample size reduction of 5.5% compared with modified AS for observational studies of CAC progression and for randomized clinical trials.
CONCLUSION: There is significantly reduced interscan variability of CAC measurements with mineral mass compared with the modified AS or VS. However, the measurement variability of all quantification methods is predicted by the amount of CAC and is inversely correlated to the extent of partial volume artifacts. Moreover, the improvement of measurement reproducibility leads to a modest reduction in sample size for observational epidemiological studies or randomized clinical trials to assess the progression of CAC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434160     DOI: 10.1016/j.ejrad.2005.12.027

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  55 in total

1.  Prevalence and distribution of abdominal aortic calcium by gender and age group in a community-based cohort (from the Framingham Heart Study).

Authors:  Michael L Chuang; Joseph M Massaro; Yamini S Levitzky; Caroline S Fox; Emily S Manders; Udo Hoffmann; Christopher J O'Donnell
Journal:  Am J Cardiol       Date:  2012-06-20       Impact factor: 2.778

2.  QCT Volumetric Bone Mineral Density and Vascular and Valvular Calcification: The Framingham Study.

Authors:  Jimmy J Chan; L Adrienne Cupples; Douglas P Kiel; Christopher J O'Donnell; Udo Hoffmann; Elizabeth J Samelson
Journal:  J Bone Miner Res       Date:  2015-05-06       Impact factor: 6.741

3.  Prevalence of anatomic impediments to interlaminar lumbar epidural steroid injection.

Authors:  Farah Hameed; David J Hunter; James Rainville; Ling Li; Pradeep Suri
Journal:  Arch Phys Med Rehabil       Date:  2012-02       Impact factor: 3.966

4.  Coronary artery calcium screening: current status and recommendations from the European Society of Cardiac Radiology and North American Society for Cardiovascular Imaging.

Authors:  Matthijs Oudkerk; Arthur E Stillman; Sandra S Halliburton; Willi A Kalender; Stefan Möhlenkamp; Cynthia H McCollough; Rozemarijn Vliegenthart; Leslee J Shaw; William Stanford; Allen J Taylor; Peter M A van Ooijen; Lewis Wexler; Paolo Raggi
Journal:  Eur Radiol       Date:  2008-07-24       Impact factor: 5.315

5.  Relation of Iliac Artery Calcium With Adiposity Measures and Peripheral Artery Disease.

Authors:  Jane J Lee; Alison Pedley; Ido Weinberg; Kathryn A Britton; Joseph M Massaro; Udo Hoffmann; Emily Manders; Caroline S Fox; Joanne M Murabito
Journal:  Am J Cardiol       Date:  2017-01-25       Impact factor: 2.778

6.  Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.

Authors:  Amit Pursnani; Joseph M Massaro; Ralph B D'Agostino; Christopher J O'Donnell; Udo Hoffmann
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

7.  Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study.

Authors:  Amit Pursnani; Joseph M Massaro; Ralph B D'Agostino; Christopher J O'Donnell; Udo Hoffmann
Journal:  J Clin Oncol       Date:  2017-07-12       Impact factor: 44.544

8.  Coronary artery calcium assessed with calibrated mass scoring in asymptomatic individuals: results from the Copenhagen General Population Study.

Authors:  Andreas D Knudsen; Andreas Fuchs; J Tobias Kühl; Ben A Arnold; Børge G Nordestgaard; Lars V Køber; Klaus F Kofoed
Journal:  Eur Radiol       Date:  2018-05-03       Impact factor: 5.315

9.  Computed tomography-evaluated features of spinal degeneration: prevalence, intercorrelation, and association with self-reported low back pain.

Authors:  Leonid Kalichman; David H Kim; Ling Li; Ali Guermazi; David J Hunter
Journal:  Spine J       Date:  2009-12-16       Impact factor: 4.166

10.  Facet orientation and tropism: associations with facet joint osteoarthritis and degeneratives.

Authors:  Leonid Kalichman; Pradeep Suri; Ali Guermazi; Ling Li; David J Hunter
Journal:  Spine (Phila Pa 1976)       Date:  2009-07-15       Impact factor: 3.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.